AR086168A1 - Procesos para la elaboracion de depsipeptidos macrociclicos e intermediarios - Google Patents
Procesos para la elaboracion de depsipeptidos macrociclicos e intermediariosInfo
- Publication number
- AR086168A1 AR086168A1 ARP120101326A ARP120101326A AR086168A1 AR 086168 A1 AR086168 A1 AR 086168A1 AR P120101326 A ARP120101326 A AR P120101326A AR P120101326 A ARP120101326 A AR P120101326A AR 086168 A1 AR086168 A1 AR 086168A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- amino acid
- salt
- alkanoyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 108010002156 Depsipeptides Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 11
- 229940024606 amino acid Drugs 0.000 abstract 6
- 235000001014 amino acid Nutrition 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 3
- 229960000310 isoleucine Drugs 0.000 abstract 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 3
- 239000004474 valine Substances 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- 125000006239 protecting group Chemical group 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 238000007086 side reaction Methods 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cookers (AREA)
- Cereal-Derived Products (AREA)
Abstract
Reivindicación 1: Un método o proceso para la preparación de un compuesto de depsipéptido cíclico de la fórmula (1), en donde: A1 es una fracción bivalente de un aminoácido con un grupo carboxilo o carbamoilo terminal, en especial asparagina o glutamina, y se enlaza en su lado derecho en la fórmula (1) por medio de un carbonilo con el resto de la molécula; o es alcanoílo C1-8 o hidroxi-alcanoílo C1-8 fosforilado; X se enlaza por medio de un N de A1 y es acilo, o está ausente si A1 es alcanoílo C1-8 o hidroxi-alcanoílo C1-8 fosforilado; R2 es alquilo C1-8, en especial metilo; R3 es la cadena lateral de un aminoácido, en especial de leucina, isoleucina o valina; R5 es la cadena lateral de un aminoácido, de preferencia de fenilalanina, leucina, isoleucina o valina; R6 es la cadena lateral de un hidroxi-aminoácido, en especial de tirosina; R7 es la cadena lateral de un aminoácido, de preferencia del aminoácido leucina, isoleucina o valina; e Y es hidrógeno o alquilo C1-8; o una sal del mismo, comprendiendo este método: desproteger selectivamente un compuesto de la fórmula (2) en donde Prot es un grupo protector, Y es como se define para un compuesto de la fórmula (1), y X*, A1*, R2*, R3*, R5*, R6*, y R7* corresponden a X, A1, R2, R3, R5, R6, y R7 en la fórmula (1), respectivamente, pero con la condición de que los grupos funcionales reactivos sobre estas fracciones están presentes en una forma protegida cuando menos si podrían participar en reacciones secundarias indeseadas, para dar como resultado un compuesto de la fórmula (3), en donde X*, A1*, R2*, R3*, R5*, R6*, y R7* tienen los significados definidos anteriormente, hacer reaccionar el grupo hidroxilo libre bajo condiciones de oxidación para formar un compuesto de la fórmula (4), y remover los grupos protectores restantes para proporcionar un compuesto de la fórmula (1), o una sal del mismo, y, opcionalmente, convertir un compuesto libre de la fórmula (1) en una sal, una sal de un compuesto de la fórmula (1) en una sal diferente de un compuesto de la fórmula (1) o en el compuesto libre de la fórmula (1), y/o convertir un análogo deshidratado de un compuesto de la fórmula (1) en el compuesto correspondiente de la formula (1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477319P | 2011-04-20 | 2011-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086168A1 true AR086168A1 (es) | 2013-11-27 |
Family
ID=46317455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101326A AR086168A1 (es) | 2011-04-20 | 2012-04-18 | Procesos para la elaboracion de depsipeptidos macrociclicos e intermediarios |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8614289B2 (es) |
| EP (1) | EP2699585A1 (es) |
| JP (2) | JP5951006B2 (es) |
| KR (1) | KR101580729B1 (es) |
| CN (2) | CN103476789B (es) |
| AR (1) | AR086168A1 (es) |
| AU (1) | AU2012245980B2 (es) |
| BR (1) | BR112013026660A2 (es) |
| CA (1) | CA2833109A1 (es) |
| CL (2) | CL2013003037A1 (es) |
| CO (1) | CO6801799A2 (es) |
| EA (2) | EA201500734A1 (es) |
| GT (1) | GT201300256A (es) |
| IL (1) | IL228727A0 (es) |
| MA (1) | MA35034B1 (es) |
| MX (1) | MX337526B (es) |
| PE (1) | PE20141206A1 (es) |
| SG (1) | SG193918A1 (es) |
| TN (1) | TN2013000385A1 (es) |
| TW (1) | TW201249863A (es) |
| WO (1) | WO2012143888A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY151973A (en) | 2007-08-17 | 2014-07-31 | Novartis Ag | Cyclic depsipeptides |
| US8614289B2 (en) | 2011-04-20 | 2013-12-24 | Novartis Ag | Processes for the manufacture of macrocyclic depsipeptides and new intermediates |
| US8680054B2 (en) | 2011-04-20 | 2014-03-25 | Novartis Ag | Suspension type topical formulations comprising cyclic depsipeptide |
| US9067978B2 (en) * | 2012-10-09 | 2015-06-30 | Novartis Ag | Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates |
| US8987413B2 (en) | 2012-10-09 | 2015-03-24 | Novartis Ag | Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates |
| WO2015155676A1 (en) | 2014-04-08 | 2015-10-15 | Novartis Ag | Novel aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates |
| TWI749509B (zh) * | 2015-05-20 | 2021-12-11 | 美商百靈佳殷格翰動物保健美國有限公司 | 驅蟲酯肽化合物 |
| US10683325B2 (en) | 2015-09-17 | 2020-06-16 | Massachusetts Institute Of Technology | Methods and systems for solid phase peptide synthesis |
| KR102031186B1 (ko) * | 2017-01-11 | 2019-11-08 | 주식회사 엘지생활건강 | 단백질 강도 강화용 조성물 |
| US11643438B2 (en) | 2018-07-20 | 2023-05-09 | The Board Of Regents Of The University Of Oklahoma | Antimicrobial peptides and methods of use |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3043252C2 (de) | 1980-11-15 | 1982-12-02 | Degussa Ag, 6000 Frankfurt | Cyclische Acetale von N-Acylglutaminsäure -γ- semialdehyden, Verfahren zu deren Herstellung und ihre Verwendung |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| DE4421113A1 (de) | 1994-06-16 | 1995-12-21 | Biotechnolog Forschung Gmbh | Chondramide, Gewinnungsverfahren, Mittel mit Chondramiden und Mischkultur zur Chondramid-Gewinnung |
| DE19828043A1 (de) | 1998-06-24 | 1999-12-30 | Bayer Ag | Ektoparasitizide Mittel |
| JP2000154198A (ja) | 1998-11-20 | 2000-06-06 | Nisshin Flour Milling Co Ltd | 環状デプシペプチドの固相合成方法及びその中間体 |
| GB0108234D0 (en) * | 2001-04-02 | 2001-05-23 | Pharma Mar Sa | Process for producing trunkamide A compounds |
| US20040110228A1 (en) | 2002-04-01 | 2004-06-10 | Mcalpine Shelli R. | Combinatorial organic synthesis of unique biologically active compounds |
| US7872052B2 (en) | 2003-06-06 | 2011-01-18 | Arexis Ab | Use of heterocyclic compounds as SCCE inhibitors |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| WO2005075667A1 (en) | 2004-02-03 | 2005-08-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with kallikrein 7 (klk7) |
| AU2007220042A1 (en) | 2006-02-27 | 2007-09-07 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Identification and use of novopeptides for the treatment of cancer |
| GB0715750D0 (en) | 2007-08-13 | 2007-09-19 | Karus Therapeutics Ltd | Chemical compounds |
| MY151973A (en) | 2007-08-17 | 2014-07-31 | Novartis Ag | Cyclic depsipeptides |
| US8415305B2 (en) | 2007-08-17 | 2013-04-09 | Novartis Ag | Use of cyclic depsipeptides to inhibit kallikrein 7 |
| DE102007052391A1 (de) | 2007-10-31 | 2009-05-07 | Henkel Ag & Co. Kgaa | Mattwachs |
| US20110112121A1 (en) | 2009-07-06 | 2011-05-12 | Joerg Berghausen | Pharmaceutical Compositions and Solid Forms |
| US20120064013A1 (en) | 2010-02-03 | 2012-03-15 | David Marcos | Foamable topical composition |
| KR101004362B1 (ko) | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제 |
| US20120064136A1 (en) | 2010-09-10 | 2012-03-15 | Nanobio Corporation | Anti-aging and wrinkle treatment methods using nanoemulsion compositions |
| EP2667859A2 (en) | 2011-01-24 | 2013-12-04 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
| DK2667854T3 (en) | 2011-01-24 | 2019-04-23 | Anterios Inc | NANO PARTICLE FORMATIONS |
| US8614289B2 (en) | 2011-04-20 | 2013-12-24 | Novartis Ag | Processes for the manufacture of macrocyclic depsipeptides and new intermediates |
| US8680054B2 (en) | 2011-04-20 | 2014-03-25 | Novartis Ag | Suspension type topical formulations comprising cyclic depsipeptide |
| US8987413B2 (en) | 2012-10-09 | 2015-03-24 | Novartis Ag | Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates |
| US9067978B2 (en) | 2012-10-09 | 2015-06-30 | Novartis Ag | Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates |
| WO2015155676A1 (en) | 2014-04-08 | 2015-10-15 | Novartis Ag | Novel aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates |
-
2012
- 2012-04-18 US US13/449,937 patent/US8614289B2/en not_active Expired - Fee Related
- 2012-04-18 AR ARP120101326A patent/AR086168A1/es unknown
- 2012-04-19 BR BR112013026660A patent/BR112013026660A2/pt not_active IP Right Cessation
- 2012-04-19 MX MX2013012188A patent/MX337526B/es active IP Right Grant
- 2012-04-19 AU AU2012245980A patent/AU2012245980B2/en not_active Ceased
- 2012-04-19 KR KR1020137030625A patent/KR101580729B1/ko not_active IP Right Cessation
- 2012-04-19 CA CA2833109A patent/CA2833109A1/en not_active Abandoned
- 2012-04-19 TW TW101114027A patent/TW201249863A/zh unknown
- 2012-04-19 CN CN201280019062.6A patent/CN103476789B/zh not_active Expired - Fee Related
- 2012-04-19 EP EP12727933.9A patent/EP2699585A1/en not_active Withdrawn
- 2012-04-19 WO PCT/IB2012/051977 patent/WO2012143888A1/en active Application Filing
- 2012-04-19 PE PE2013002370A patent/PE20141206A1/es not_active Application Discontinuation
- 2012-04-19 CN CN201510232322.3A patent/CN104804072A/zh active Pending
- 2012-04-19 EA EA201500734A patent/EA201500734A1/ru unknown
- 2012-04-19 JP JP2014505772A patent/JP5951006B2/ja not_active Expired - Fee Related
- 2012-04-19 EA EA201391554A patent/EA025546B1/ru not_active IP Right Cessation
- 2012-04-19 SG SG2013070453A patent/SG193918A1/en unknown
- 2012-04-19 MA MA36321A patent/MA35034B1/fr unknown
-
2013
- 2013-09-25 TN TNP2013000385A patent/TN2013000385A1/fr unknown
- 2013-10-03 IL IL228727A patent/IL228727A0/en unknown
- 2013-10-18 GT GT201300256A patent/GT201300256A/es unknown
- 2013-10-18 CL CL2013003037A patent/CL2013003037A1/es unknown
- 2013-10-24 CO CO13252979A patent/CO6801799A2/es unknown
- 2013-11-18 US US14/082,315 patent/US9278997B2/en active Active
-
2015
- 2015-03-18 CL CL2015000688A patent/CL2015000688A1/es unknown
-
2016
- 2016-03-07 JP JP2016043330A patent/JP2016164158A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086168A1 (es) | Procesos para la elaboracion de depsipeptidos macrociclicos e intermediarios | |
| CY1123549T1 (el) | Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης | |
| CY1120031T1 (el) | Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης | |
| BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
| ECSP14013245A (es) | Nuevos derivados dihidroquinolina-2-ona | |
| MA33803B1 (fr) | Inhibiteur de bromodomaine de benzodiazépine | |
| BR112013020042A2 (pt) | inibidores de vírus da hepatite c | |
| EA201500653A1 (ru) | Композиции, содержащие триазольное соединение | |
| CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| BR112015014253A2 (pt) | produtos de higiene bucal que compreendem um complexo de haleto de aminoácido e zinco tetrabásico | |
| MX2013006378A (es) | Catalizadores de blanqueo. | |
| BR112013016595A2 (pt) | inibidores de neprilisina | |
| TR201900128T4 (tr) | Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller. | |
| UY33665A (es) | Derivado peptídico | |
| BRPI1106572B8 (pt) | Composições que compreendem um retinoide e um inibidor de nfkb e seus métodos de uso | |
| BR112015012825A2 (pt) | piridopirazinas substituídas como inibidores de syk | |
| BR112014002594A2 (pt) | uso de diésteres de isossorbida como espessantes | |
| AR092948A1 (es) | Procesos en fase liquida para la elaboracion de depsipeptidos macrociclicos y de intermediarios | |
| BR112013003216A2 (pt) | composições sintéticas de ácido biliar e métodos | |
| EA201170294A1 (ru) | Способы лечения реперфузионных повреждений | |
| UY33014A (es) | Nuevos compuestos de diazinil-pirazolilo | |
| MX2014015884A (es) | Compuestos antivirales. | |
| BR112014002570A2 (pt) | uso de monoésteres de isossorbida como espessantes | |
| EA201491978A1 (ru) | Резиновые композиции | |
| PH12014502285A1 (en) | Anti-malarial agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |